Deciphera Pharmaceuticals, Inc. NASDAQ:DCPH

Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9

Deciphera Pharmaceuticals stock price monthly change

+0.91%
month

Deciphera Pharmaceuticals stock price quarterly change

+64.25%
quarter

Deciphera Pharmaceuticals stock price yearly change

+85.57%
year

Deciphera Pharmaceuticals key metrics

Market Cap
2.21B
Enterprise value
1.07B
P/E
-6.62
EV/Sales
8.00
EV/EBITDA
-6.28
Price/Sales
8.27
Price/Book
3.24
PEG ratio
-0.12
EPS
-2.21
Revenue
174.91M
EBITDA
-203.92M
Income
-190.41M
Revenue Q/Q
34.54%
Revenue Y/Y
26.50%
Profit margin
-133.49%
Oper. margin
-136.32%
Gross margin
93.46%
EBIT margin
-136.32%
EBITDA margin
-116.59%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Deciphera Pharmaceuticals stock price history

Deciphera Pharmaceuticals stock forecast

Deciphera Pharmaceuticals financial statements

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH): Profit margin
Jun 2023 38.30M -48.56M -126.78%
Sep 2023 43.31M -49.58M -114.47%
Dec 2023 48.29M -47.19M -97.71%
Mar 2024 44.99M -45.08M -100.19%
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH): Analyst Estimates
Mar 2024 44.99M -45.08M -100.19%
Sep 2025 66.8M -27.74M -41.53%
Oct 2025 62.53M -36.41M -58.23%
Dec 2025 72.5M -27.09M -37.37%
  • Analysts Price target

  • Financials & Ratios estimates

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH): Earnings per share (EPS)
2023-05-03 -0.6 -0.6
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH): Debt to assets
Jun 2023 509618000 105.18M 20.64%
Sep 2023 497836000 116.16M 23.33%
Dec 2023 473566000 122.65M 25.9%
Mar 2024 420928000 104.87M 24.92%
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH): Cash Flow
Jun 2023 -38.62M 4.36M 838K
Sep 2023 -29.80M 41.40M 15.59M
Dec 2023 -28.80M 2.19M 890K
Mar 2024 -54.58M 62.63M 522K

Deciphera Pharmaceuticals alternative data

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH): Employee count
Aug 2023 300
Sep 2023 300
Oct 2023 300
Nov 2023 300
Dec 2023 300
Jan 2024 300
Feb 2024 300
Mar 2024 355
Apr 2024 355
May 2024 355
Jun 2024 355
Jul 2024 355

Deciphera Pharmaceuticals other data

75.02% -4.02%
of DCPH is owned by hedge funds
43.58M -2.33M
shares is hold by hedge funds

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH): Insider trades (number of shares)
Period Buy Sel
Mar 2023 0 7500
May 2023 11000 0
Jun 2023 10000 7441
Oct 2023 0 32005
Nov 2023 0 17801
Dec 2023 0 39637
Jan 2024 0 8118
Feb 2024 0 10159
Transaction Date Insider Security Shares Price per share Total value Source
Sale
SHERMAN MATTHEW L officer: EVP & Ch.. Common Stock 2,615 $15.62 $40,841
Sale
KELLY THOMAS PATRICK officer: Chief Fi.. Common Stock 3,010 $15.62 $47,010
Sale
PITMAN JAMA officer: SVP, Chief Development..
Common Stock 2,267 $15.62 $35,406
Sale
MARTIN DANIEL C. officer: Chief Co.. Common Stock 2,267 $15.62 $35,406
Sale
SHERMAN MATTHEW L officer: EVP & Ch.. Common Stock 2,435 $14.47 $35,234
Sale
PITMAN JAMA officer: SVP, Chief Development..
Common Stock 1,624 $14.47 $23,499
Sale
MARTIN DANIEL C. officer: Chief Co.. Common Stock 1,624 $14.47 $23,499
Sale
KELLY THOMAS PATRICK officer: Chief Fi.. Common Stock 2,435 $14.47 $35,234
Sale
HOERTER STEVEN L. director, officer.. Common Stock 30,664 $15.37 $471,214
Sale
KELLY THOMAS PATRICK officer: Chief Fi.. Common Stock 2,792 $15.37 $42,905
Thursday, 18 July 2024
businesswire.com
Monday, 3 June 2024
businesswire.com
Thursday, 23 May 2024
zacks.com
Friday, 10 May 2024
Zacks Investment Research
Zacks Investment Research
Tuesday, 30 April 2024
Reuters
Monday, 29 April 2024
Invezz
InvestorPlace
Barrons
Market Watch
Reuters
Thursday, 7 March 2024
Zacks Investment Research
Wednesday, 28 February 2024
Zacks Investment Research
Monday, 12 February 2024
Zacks Investment Research
Wednesday, 7 February 2024
Zacks Investment Research
Thursday, 1 February 2024
Business Wire
Tuesday, 9 January 2024
Seeking Alpha
Sunday, 7 January 2024
Seeking Alpha
Tuesday, 2 January 2024
Business Wire
Tuesday, 31 October 2023
Zacks Investment Research
Monday, 30 October 2023
Zacks Investment Research
Tuesday, 22 August 2023
Seeking Alpha
Monday, 21 August 2023
InvestorPlace
Saturday, 19 August 2023
The Motley Fool
Friday, 11 August 2023
The Motley Fool
Thursday, 10 August 2023
Zacks Investment Research
Sunday, 18 June 2023
Seeking Alpha
Friday, 2 June 2023
Zacks Investment Research
Monday, 8 May 2023
Business Wire
Sunday, 7 May 2023
Seeking Alpha
  • When is Deciphera Pharmaceuticals's next earnings date?

    Unfortunately, Deciphera Pharmaceuticals's (DCPH) next earnings date is currently unknown.

  • Does Deciphera Pharmaceuticals pay dividends?

    No, Deciphera Pharmaceuticals does not pay dividends.

  • How much money does Deciphera Pharmaceuticals make?

    Deciphera Pharmaceuticals has a market capitalization of 2.21B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 21.87% to 163.36M US dollars. Deciphera Pharmaceuticals made a loss 194.94M US dollars in net income (profit) last year or -$0.6 on an earnings per share basis.

  • What is Deciphera Pharmaceuticals's stock symbol?

    Deciphera Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "DCPH".

  • What is Deciphera Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.

  • How do i buy shares of Deciphera Pharmaceuticals?

    Shares of Deciphera Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Deciphera Pharmaceuticals's key executives?

    Deciphera Pharmaceuticals's management team includes the following people:

    • Mr. Steven L. Hoerter Pres, Chief Executive Officer & Director(age: 54, pay: $1,200,000)
    • Dr. Matthew L. Sherman Executive Vice President & Chief Medical Officer(age: 69, pay: $818,410)
    • Mr. Thomas Patrick Kelly J.D. Executive Vice President, Chief Financial Officer & Treasurer(age: 54, pay: $726,860)
    • Dr. Daniel L. Flynn Ph.D. Executive Vice President, Chief Scientific Officer & Founder(age: 70, pay: $722,510)
    • Mr. Daniel C. Martin Senior Vice President & Chief Commercial Officer(age: 50, pay: $707,820)
    • Dr. Stephen B. Ruddy Ph.D. Senior Vice President & Chief Technical Officer(age: 61, pay: $601,540)
  • Is Deciphera Pharmaceuticals founder-led company?

    Yes, Deciphera Pharmaceuticals is a company led by its founder Dr. Daniel L. Flynn Ph.D..

  • How many employees does Deciphera Pharmaceuticals have?

    As Jul 2024, Deciphera Pharmaceuticals employs 355 workers.

  • When Deciphera Pharmaceuticals went public?

    Deciphera Pharmaceuticals, Inc. is publicly traded company for more then 7 years since IPO on 28 Sep 2017.

  • What is Deciphera Pharmaceuticals's official website?

    The official website for Deciphera Pharmaceuticals is deciphera.com.

  • Where are Deciphera Pharmaceuticals's headquarters?

    Deciphera Pharmaceuticals is headquartered at 200 Smith Street, Waltham, MA.

  • How can i contact Deciphera Pharmaceuticals?

    Deciphera Pharmaceuticals's mailing address is 200 Smith Street, Waltham, MA and company can be reached via phone at +7 812096400.

Deciphera Pharmaceuticals company profile:

Deciphera Pharmaceuticals, Inc.

deciphera.com
Exchange:

NASDAQ

Full time employees:

355

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

200 Smith Street
Waltham, MA 02451

CIK: 0001654151
ISIN: US24344T1016
CUSIP: 24344T101